Curing inflammatory diseases using phosphorous dendrimers - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue WIREs Nanomedicine and Nanobiotechnology Année : 2022

Curing inflammatory diseases using phosphorous dendrimers

Résumé

Different types of water-soluble phosphorous dendrimers have been synthesized and display many different biological properties. It has been shown in particular that phosphorous dendrimers of first generation functionalized with azabisphosphonate terminal functions are able to stimulate the human immune system ex vivo. These dendrimers are internalized by monocytes within a few seconds, and induce their anti-inflammatory activation. The presence of the dendrimers induces also the inhibition of the differentiation of monocytes into osteoclasts, the maturation of dendritic cells, and inhibits the proliferation of the proinflammatory CD4+ T lymphocytes. Finally, after 2–3 weeks of culture of peripheral blood mononuclear cells, amplifications by several tens of natural killer cells is observed. In view of all these properties, the influence of these azabisphosphonate-dendrimers has been tested in vivo with several animal models, against different chronic or acute inflammatory diseases, such as multiple sclerosis, rheumatoid arthritis, uveitis, and psoriasis, but also against myeloid leukemia, a hematological cancer. The hematological safety has been demonstrated in mice, as there is no platelet aggregation, no hemolysis, and no disturbance in the hematological formula. The safety of the azabisphosphonate-dendrimer has been assessed also with non-human primates (cynomolgus monkeys) which received repeated injections, as a de-risking pre-clinical test. Biochemical, hematological, and all immunological parameters in peripheral blood remained within a normal physiological range throughout the study, and all survived well. Other phosphorous dendrimers also display anti-inflammatory properties in vivo, in particular dendrimers functionalized with mannose derivatives, which prevent acute lung diseases when given orally (per os) to mice.

Mots clés

Fichier principal
Vignette du fichier
Caminade, Curing inflammatory diseases, 2022.pdf (2.8 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03597831 , version 1 (04-03-2022)

Identifiants

Citer

Anne-Marie Caminade, Cédric-Olivier Turrin, Rémy Poupot. Curing inflammatory diseases using phosphorous dendrimers. WIREs Nanomedicine and Nanobiotechnology, 2022, 14 (4), pp.e1783. ⟨10.1002/wnan.1783⟩. ⟨hal-03597831⟩
25 Consultations
347 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More